EFG Capital International’s BioMarin Pharmaceuticals BMRN Stock Holding History

EFG Capital International’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.44M	Buy	+16,602	New	+$1.56M	0.33%	82

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

EFG Capital International's BMRN Position: Q2 2023 in Review

EFG Capital International opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2023: 16,602 shares worth $1.44M. The stake represents 0.33% of the portfolio and ranks #82 among its holdings.

557 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

EFG Capital International held 16,602 shares of BioMarin Pharmaceuticals worth $1.44M as of Q2 2023.
BioMarin Pharmaceuticals was a new EFG Capital International position in Q2 2023.
BioMarin Pharmaceuticals made up 0.33% of EFG Capital International's portfolio in Q2 2023, its #82 holding.
557 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on EFG Capital International's 13F filing for Q2 2023, filed 2 Aug 2023.